梅花生物
(600873)
| 流通市值：306.39亿 | | | 总市值：306.39亿 |
| 流通股本：28.53亿 | | | 总股本：28.53亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 18,680,785,476.06 | 12,642,718,053.37 | 6,486,560,309.24 | 27,760,612,259.07 |
| 营业收入 | 18,680,785,476.06 | 12,642,718,053.37 | 6,486,560,309.24 | 27,760,612,259.07 |
| 二、营业总成本 | 16,648,960,494.8 | 11,156,817,653.82 | 5,754,966,816.91 | 24,158,622,972 |
| 营业成本 | 15,149,363,557.23 | 10,177,206,263.13 | 5,232,609,548.22 | 22,297,122,025.25 |
| 税金及附加 | 175,637,343.6 | 115,408,867.54 | 54,100,872.32 | 242,593,736.35 |
| 销售费用 | 290,839,474.29 | 204,453,466.84 | 109,209,195.68 | 413,512,921.96 |
| 管理费用 | 819,350,604.16 | 554,506,366.51 | 302,966,862.94 | 924,598,280.87 |
| 研发费用 | 285,461,019.6 | 180,479,234.74 | 90,844,311.14 | 314,222,682.89 |
| 财务费用 | -71,691,504.08 | -75,236,544.94 | -34,763,973.39 | -33,426,675.32 |
| 其中:利息费用 | 65,518,228.32 | 46,859,883.13 | 23,644,161.14 | 115,220,289.9 |
| 其中:利息收入 | 83,996,787.45 | 59,735,278.47 | 34,617,303.5 | 118,865,910.23 |
| 加:公允价值变动收益 | 8,763,064.93 | 1,959,926.94 | 260,000.32 | -38,116,002.85 |
| 加:投资收益 | 20,742,760.03 | 14,671,408.04 | 3,912,130.43 | 7,627,189.35 |
| 资产处置收益 | -2,427,954.12 | 1,598,224.17 | 468,261.36 | 4,073,026.92 |
| 资产减值损失(新) | -1,857,388.63 | -1,987,907.91 | - | -5,415,349.06 |
| 信用减值损失(新) | 6,173,620.92 | 6,162,617.22 | - | -5,225,785.54 |
| 其他收益 | 210,447,791.63 | 174,432,864.62 | 149,619,138.69 | 248,461,028.47 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 2,273,666,876.02 | 1,682,737,532.63 | 885,853,023.13 | 3,813,393,394.36 |
| 加:营业外收入 | 105,472,109.03 | 66,373,971.73 | 839,433.54 | 10,357,039.99 |
| 减:营业外支出 | 37,189,601.53 | 31,820,702.21 | 11,161,236.8 | 100,614,814.2 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 2,341,949,383.52 | 1,717,290,802.15 | 875,531,219.87 | 3,723,135,620.15 |
| 减:所得税费用 | 346,627,735.23 | 243,467,012.23 | 123,826,654.08 | 542,185,924.67 |
| 六、净利润 | 1,995,321,648.29 | 1,473,823,789.92 | 751,704,565.79 | 3,180,949,695.48 |
| 持续经营净利润 | 1,995,321,648.29 | 1,473,823,789.92 | 751,704,565.79 | 3,180,949,695.48 |
| 归属于母公司股东的净利润 | 1,995,321,648.29 | 1,473,823,789.92 | 751,704,565.79 | 3,180,949,695.48 |
| (一)基本每股收益 | 0.68 | 0.5 | 0.26 | 1.06 |
| (二)稀释每股收益 | 0.68 | 0.5 | 0.26 | 1.06 |
| 八、其他综合收益 | 39,914,573.3 | -30,039,576.1 | 10,898,041.98 | -535,384,994.54 |
| 归属于母公司股东的其他综合收益 | 39,914,573.3 | -30,039,576.1 | 10,898,041.98 | -535,384,994.54 |
| 九、综合收益总额 | 2,035,236,221.59 | 1,443,784,213.82 | 762,602,607.77 | 2,645,564,700.94 |
| 归属于母公司股东的综合收益总额 | 2,035,236,221.59 | 1,443,784,213.82 | 762,602,607.77 | 2,645,564,700.94 |
| 公告日期 | 2024-10-23 | 2024-07-30 | 2024-04-09 | 2024-03-19 |
| 审计意见(境内) | | | | 标准无保留意见 |